John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about the four-year update on the outcomes of the MURANO study, investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Phase 3 MURANO Trial
